Aug 6 (Reuters) - Two more doses of Novo Nordisk's

weight-loss drug, Wegovy, is now available, the U.S.

Food and Drug Administration's updated shortage list showed on

Tuesday.

Several doses of Novo's Ozempic and Wegovy, both chemically

known as semaglutide, have been on the U.S. health regulator's

shortage list since early 2022.

According to the website, the drug's smallest dose of 0.25

milligram (mg) is listed under limited availability, while all

other doses are listed as available.

(Reporting by Christy Santhosh; Editing by Anil D'Silva)